Reflecting the urgency to develop prophylactic approaches against COVID-19, several vaccine candidates have entered clinical trials before showing efficacy in animal models. In this preprint, Corbett et al. describe a preclinical study evaluating an mRNA vaccine candidate by Moderna. Immunization of mice with mRNA encoding stabilized prefusion SARS-CoV-2 spike trimers elicited dose-dependent neutralizing antibody and CD8+ T cell responses. Two doses given in prime–boost combination (2 x 1 µg/mouse) protected mice against infection of the nasal mucosa and lungs after challenge with mouse-adapted SARS-CoV-2. Importantly, there was no indication of enhanced immunopathology in animals that received sub-protective doses. A phase III efficacy trial in humans (using a single 100 µg dose regimen) is set to start in July.
References
Original article
Corbett, K. S. et al. SARS-CoV-2 mRNA vaccine development enabled by prototype pathogen preparedness. Preprint at bioRxiv https://doi.org/10.1101/2020.06.11.145920 (2020)
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares no competing interests.
Rights and permissions
About this article
Cite this article
Vabret, N. Preclinical data from SARS-CoV-2 mRNA vaccine. Nat Rev Immunol 20, 461 (2020). https://doi.org/10.1038/s41577-020-0377-3
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41577-020-0377-3
This article is cited by
-
The safety of Covid-19 mRNA vaccines: a review
Patient Safety in Surgery (2021)